Novartis's Menveo gains EU approval
This article was originally published in Scrip
Executive Summary
Novartis's quadrivalent conjugated meningococcal vaccine Menveo (meningococcal (groups A, C, W-135) oligosaccharide diphtheria CRM197 conjugate vaccine) has been approved in the EU for the active immunisation of persons over the age of 11 years who are at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.